Genisphere and the Lankenau Institute for Medical Research (LIMR) have partnered to develop nanotherapeutics targeting cancers and eye diseases. This partnership expands an existing collaboration to identify inflammatory bowel disease biomarkers.
Genisphere will use its 3DNA dendrimer, which allows researchers to deliver a therapeutic agent to any target cell. It is manufactured from natural strands of DNA hybridized together to create high biocompatibility and low toxicity. With the dendrimer technology, LIMR researchers are using targeted drug delivery to treat ovarian, cervical, prostate and pancreatic cancer, as well as a therapy that uses small molecule drugs to target cells that cause post-cataract surgery eye lesions.
"LIMR is fortunate to partner with Genisphere for the development of its cancer nanotherapies,” said George Prendergast, Ph.D., president and chief executive officer of LIMR. “Given the wonderful intersection of these two organizations, we will have the right tools and skill sets to strengthen the path forward for clinical testing and ultimately commercialization."
“LIMR, with its team of talented scientists, is an ideal partner for us to study how certain therapeutics work with our DNA dendrimer nanoparticles,” said Bob Getts, chief science officer of Genisphere.